Table 4 Adverse effects (any grades) of immune checkpoint inhibitors after pemetrexed treatment failure
Adverse effects | Long-term administration ( n = 11) | Intermediate-term administration ( n = 16) | Short-term administration ( n = 55) |
|---|---|---|---|
irAE | 5 (45.5%) * | 3 (18.8%) | 10 (18.2%) |
ILD | 4 (36.3%) | 2 (12.5%) | 2 (3.6%) |
Others | 1 (9.1%) | 1 (6.3%) | 9 (16.4%) |